These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 33217360)

  • 21. Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia.
    Baer C; Dicker F; Kern W; Haferlach T; Haferlach C
    Leukemia; 2017 Jun; 31(6):1355-1362. PubMed ID: 27840426
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Prevalence of MYD88 L265P and TNFAIP3 Mutations and Their Correlations with Clinico-Hematological Profile in Egyptian Patients with Diffuse Large B Cell Lymphoma.
    Elbaz O; Shaat RM; Abd El Ghaffar HA; Shamaa S; Abdel-Masseih HM; Anber N; Mortada MI
    Asian Pac J Cancer Prev; 2023 Jul; 24(7):2485-2491. PubMed ID: 37505783
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.
    Xu L; Hunter ZR; Yang G; Zhou Y; Cao Y; Liu X; Morra E; Trojani A; Greco A; Arcaini L; Varettoni M; Brown JR; Tai YT; Anderson KC; Munshi NC; Patterson CJ; Manning RJ; Tripsas CK; Lindeman NI; Treon SP
    Blood; 2013 Mar; 121(11):2051-8. PubMed ID: 23321251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pleural fluid MYD88 L265P mutation supporting diagnosis and decision to treat extramedullary Waldenstrom's macroglobulinemia: a case report.
    Barnes M; Sharma P; Kumar V; Kaell A; LiPera W
    J Med Case Rep; 2020 Jul; 14(1):98. PubMed ID: 32654665
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PlentiPlex™ MYD88 Waldenström lymphoma qPCR assay: A highly sensitive method for detection of MYD88 L265P mutation.
    Viscovo M; Clemmensen ML; Fosso F; Maiolo E; Autore F; Laurenti L; Hohaus S; Chiusolo P
    Int J Lab Hematol; 2024 Aug; 46(4):665-669. PubMed ID: 38390807
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas.
    Gachard N; Parrens M; Soubeyran I; Petit B; Marfak A; Rizzo D; Devesa M; Delage-Corre M; Coste V; Laforêt MP; de Mascarel A; Merlio JP; Bouabdhalla K; Milpied N; Soubeyran P; Schmitt A; Bordessoule D; Cogné M; Feuillard J
    Leukemia; 2013 Jan; 27(1):183-9. PubMed ID: 22944768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clonotypic analysis of immunoglobulin heavy chain sequences in patients with Waldenström's macroglobulinemia: correlation with MYD88 L265P somatic mutation status, clinical features, and outcome.
    Petrikkos L; Kyrtsonis MC; Roumelioti M; Georgiou G; Efthymiou A; Tzenou T; Panayiotidis P
    Biomed Res Int; 2014; 2014():809103. PubMed ID: 25197661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells.
    Sewastianik T; Guerrera ML; Adler K; Dennis PS; Wright K; Shanmugam V; Huang Y; Tanton H; Jiang M; Kofides A; Demos MG; Dalgarno A; Patel NA; Nag A; Pinkus GS; Yang G; Hunter ZR; Jarolim P; Munshi NC; Treon SP; Carrasco RD
    Blood Adv; 2019 Nov; 3(21):3360-3374. PubMed ID: 31698464
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May Harbor MYD88 L265P Mutations.
    King RL; Gonsalves WI; Ansell SM; Greipp PT; Frederick LA; Viswanatha DS; He R; Kyle RA; Gertz MA; Kapoor P; Morice WG; Howard MT
    Am J Clin Pathol; 2016 Jun; 145(6):843-51. PubMed ID: 27329639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of the MYD88
    Wu YY; Jia MN; Cai H; Qiu Y; Zhou DB; Li J; Cao XX
    Ann Hematol; 2020 Aug; 99(8):1763-1769. PubMed ID: 32577844
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testing.
    Swerdlow SH; Kuzu I; Dogan A; Dirnhofer S; Chan JK; Sander B; Ott G; Xerri L; Quintanilla-Martinez L; Campo E
    Virchows Arch; 2016 Mar; 468(3):259-75. PubMed ID: 26454445
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features.
    Shuai W; Lin P; Strati P; Patel KP; Routbort MJ; Hu S; Wei P; Khoury JD; You MJ; Loghavi S; Tang Z; Fang H; Thakral B; Medeiros LJ; Wang W
    Blood Cancer J; 2020 Aug; 10(8):86. PubMed ID: 32848129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Composite monoclonal B-cell lymphocytosis and MYD88 L265P-positive lymphoplasmacytic lymphoma in a patient with IgM light chain amyloidosis: Case report.
    Oishi N; Inoue T; Odate T; Mochizuki K; Ohashi K; Kirito K; Kondo T
    Pathol Int; 2020 Jul; 70(7):458-462. PubMed ID: 32323419
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets.
    Bogusz AM; Bagg A
    Leuk Lymphoma; 2016 Sep; 57(9):1991-2013. PubMed ID: 27121112
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Alcoceba M; García-Álvarez M; Medina A; Maldonado R; González-Calle V; Chillón MC; Sarasquete ME; González M; García-Sanz R; Jiménez C
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628381
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The clinical features of patients with lymphoplasmacytic diseases harboring MyD88 L265P mutation].
    Ren Y; Zhou BQ; Xu Y; Fu CC; Shen HJ; Ding ZX; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2016 Dec; 37(12):1054-1059. PubMed ID: 28088969
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Relevance of the High Prevalence of MYD88 L265P Mutated Vitreoretinal Lymphoma Identified by Droplet Digital Polymerase Chain Reaction.
    Shi H; Zhou X; Chen B; Xiao J; Li Y; Zhou X; Zhou Q; Chen K; Wang Q
    Ocul Immunol Inflamm; 2021 Apr; 29(3):448-455. PubMed ID: 31603365
    [No Abstract]   [Full Text] [Related]  

  • 38. Highly sensitive
    Drandi D; Genuardi E; Dogliotti I; Ferrante M; Jiménez C; Guerrini F; Schirico ML; Mantoan B; Muccio V; Lia G; Zaccaria GM; Omedè P; Passera R; Orsucci L; Benevolo G; Cavallo F; Galimberti S; Sanz RG; Boccadoro M; Ladetto M; Ferrero S
    Haematologica; 2018 Jun; 103(6):1029-1037. PubMed ID: 29567768
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia.
    Jiménez C; Sebastián E; Chillón MC; Giraldo P; Mariano Hernández J; Escalante F; González-López TJ; Aguilera C; de Coca AG; Murillo I; Alcoceba M; Balanzategui A; Sarasquete ME; Corral R; Marín LA; Paiva B; Ocio EM; Gutiérrez NC; González M; San Miguel JF; García-Sanz R
    Leukemia; 2013 Aug; 27(8):1722-8. PubMed ID: 23446312
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MYD88, CARD11, and CD79B Oncogenic Mutations are Rare Events in the Indian Cohort of De Novo Nodal Diffuse Large B-Cell Lymphoma.
    Aggarwal V; Das A; Bal A; Srinivasan R; Das R; Prakash G; Malhotra P; Varma S
    Appl Immunohistochem Mol Morphol; 2019 Apr; 27(4):311-318. PubMed ID: 29734251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.